Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.

Carcinogenesis - 1 Feb 2013

Wroblewski David, Mijatov Branka, Mohana-Kumaran Nethia, Lai Fritz, Gallagher Stuart J, Haass Nikolas K, Zhang Xu Dong, Hersey Peter

Abstract excerpt

Although the introduction of selective v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors has been a major advance in treatment of metastatic melanoma, approximately 50% of patients have limited responses including stabilization of disease or no response at all. This study aims to identify a novel means of overcoming resistance of melanoma to killing by BRAF inhibitors. We examined the influence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biphenyl Compounds
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Membrane Potential, Mitochondrial

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Nitrophenols

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Source

Identifiers

PMID: 23087082
DOI: 10.1093/carcin/bgs330

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.PMID 23087082Read ↗

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.Semantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.Semantic proximity Read ↗

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.Semantic proximity Read ↗

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 MimeticsSemantic proximity Read ↗

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalSemantic proximity Read ↗

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.Semantic proximity Read ↗

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.Semantic proximity Read ↗

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Semantic proximity Read ↗

Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.Semantic proximity Read ↗

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survivalSemantic proximity Read ↗

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.